NO307814B1 - Farmasøytisk materiale - Google Patents

Farmasøytisk materiale

Info

Publication number
NO307814B1
NO307814B1 NO953212A NO953212A NO307814B1 NO 307814 B1 NO307814 B1 NO 307814B1 NO 953212 A NO953212 A NO 953212A NO 953212 A NO953212 A NO 953212A NO 307814 B1 NO307814 B1 NO 307814B1
Authority
NO
Norway
Prior art keywords
pharmaceutical material
colourant
pref
hydroxypropylmethylcellulose
hrs
Prior art date
Application number
NO953212A
Other languages
English (en)
Norwegian (no)
Other versions
NO953212D0 (no
NO953212L (no
Inventor
Stephen T David
Claude E Gallian
Joseph C H Chou
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO953212D0 publication Critical patent/NO953212D0/no
Publication of NO953212L publication Critical patent/NO953212L/no
Publication of NO307814B1 publication Critical patent/NO307814B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)
NO953212A 1994-09-06 1995-08-16 Farmasøytisk materiale NO307814B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/301,281 US5478572A (en) 1994-09-06 1994-09-06 Gepirone dosage form

Publications (3)

Publication Number Publication Date
NO953212D0 NO953212D0 (no) 1995-08-16
NO953212L NO953212L (no) 1996-03-07
NO307814B1 true NO307814B1 (no) 2000-06-05

Family

ID=23162703

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953212A NO307814B1 (no) 1994-09-06 1995-08-16 Farmasøytisk materiale

Country Status (24)

Country Link
US (1) US5478572A (pl)
EP (1) EP0700680B1 (pl)
JP (1) JP4540756B2 (pl)
KR (1) KR100380806B1 (pl)
CN (1) CN1096858C (pl)
AT (1) ATE186462T1 (pl)
AU (1) AU702282B2 (pl)
CA (1) CA2157323C (pl)
CY (1) CY2222B1 (pl)
CZ (1) CZ286417B6 (pl)
DE (1) DE69513254T2 (pl)
DK (1) DK0700680T3 (pl)
ES (1) ES2142432T3 (pl)
FI (1) FI117319B (pl)
GR (1) GR3032598T3 (pl)
HU (1) HU227339B1 (pl)
IL (1) IL114984A (pl)
NO (1) NO307814B1 (pl)
NZ (1) NZ272855A (pl)
PL (1) PL180691B1 (pl)
RU (1) RU2155044C2 (pl)
SG (1) SG30436A1 (pl)
TW (1) TW445152B (pl)
ZA (1) ZA957144B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060068017A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
CN100367965C (zh) * 1999-12-20 2008-02-13 法布瑞－克雷默制药有限公司 吉吡隆代谢物在制备改善哺乳动物不良心理状态的组合物上的应用
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
CA2436692A1 (en) * 2000-12-08 2002-06-13 Akzo Nobel Nv Oral extended release formulation of gepirone
IL158390A0 (en) 2001-05-01 2004-05-12 Pfizer Prod Inc Method for manufacturing a low dose pharmaceutical composition
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030152621A1 (en) * 2001-11-21 2003-08-14 Egberink J. G. J. Pharmaceutical formulation of gepirone for oral administration
TW200306866A (en) * 2002-05-07 2003-12-01 Akzo Nobel Nv A method to improve surface properties of pharmaceutical tablets
AU2003274110A1 (en) * 2002-09-24 2004-04-19 Akzo Nobel N.V. Method to improve pharmaceutical tablets having a matrix of cellulose ether
KR101087464B1 (ko) 2003-08-08 2011-11-25 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온 히드로클로라이드의 개질 방출형 정제
AR049478A1 (es) * 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
EP1781292B1 (en) * 2004-07-15 2010-09-22 Abbott Healthcare Products B.V. Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one
US20060013874A1 (en) * 2004-07-15 2006-01-19 Solvay Pharmaceuticals B.V. Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one
CA2585606A1 (en) * 2004-11-05 2006-05-18 Fabre-Kramer Pharmaceuticals, Inc. High-dosage extended-release formulation of gepirone
US20060099267A1 (en) * 2004-11-05 2006-05-11 Fabre-Kramer Pharmaceuticals, Inc. High-dosage extended-release formulation of gepirone
SI2168585T1 (sl) * 2005-06-09 2012-04-30 Euro Celtique Sa Farmacevtski sestavki nevroaktivnega steroida in njihove uporabe

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4690824A (en) * 1983-07-07 1987-09-01 Redi-Rowell, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US4782060A (en) * 1987-07-29 1988-11-01 Bristol-Myers Company Gepirone for alleviation of panic disorders
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
SE8704097D0 (sv) * 1987-10-22 1987-10-22 Astra Ab Oral formulation of buspirone and salts thereof
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5124346A (en) * 1991-04-23 1992-06-23 Pfizer Inc. Synergistic combinations in the treatment of anxiety
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5292766A (en) * 1992-03-25 1994-03-08 Eli Lilly And Company Method for improving primary memory and/or learning
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
CA2157323C (en) 2004-01-20
SG30436A1 (en) 1996-06-01
FI117319B (fi) 2006-09-15
JPH08183736A (ja) 1996-07-16
FI954154A0 (fi) 1995-09-05
CN1128142A (zh) 1996-08-07
EP0700680A1 (en) 1996-03-13
CY2222B1 (en) 2003-04-18
DE69513254T2 (de) 2000-06-15
IL114984A0 (en) 1995-12-08
KR100380806B1 (ko) 2003-07-10
AU702282B2 (en) 1999-02-18
HK1014666A1 (en) 1999-09-30
RU2155044C2 (ru) 2000-08-27
HU227339B1 (en) 2011-04-28
CZ286417B6 (en) 2000-04-12
FI954154L (fi) 1996-03-07
KR960010007A (ko) 1996-04-20
NZ272855A (en) 1997-05-26
DK0700680T3 (da) 2000-05-01
NO953212D0 (no) 1995-08-16
EP0700680B1 (en) 1999-11-10
CA2157323A1 (en) 1996-03-07
HU9502599D0 (en) 1995-11-28
DE69513254D1 (de) 1999-12-16
AU3043895A (en) 1996-03-21
GR3032598T3 (en) 2000-05-31
NO953212L (no) 1996-03-07
ZA957144B (en) 1996-03-26
US5478572A (en) 1995-12-26
ES2142432T3 (es) 2000-04-16
ATE186462T1 (de) 1999-11-15
CN1096858C (zh) 2002-12-25
PL180691B1 (en) 2001-03-30
IL114984A (en) 1999-10-28
JP4540756B2 (ja) 2010-09-08
CZ227595A3 (en) 1996-03-13
TW445152B (en) 2001-07-11
HUT73182A (en) 1996-06-28
PL310298A1 (en) 1996-03-18

Similar Documents

Publication Publication Date Title
DK0700680T3 (da) Gepirone-dosisform
NO20065390L (no) Farmasoytisk preparat i fast enhetsdoseringsform
AU646399B2 (en) Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
BR0109736A (pt) Preparação farmacêutica estabilizada, e, método para a manufatura de uma preparação farmacêutica em tablete
IS1878B (is) Nýjar efnablöndur til að nota við sykruhúðun lyfja á töfluformi
CA2321461A1 (en) Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents
BR9708772A (pt) "comprimidos famacêuticos de liberação controlada que contém um veìculo à base de amilose reticulada e hidróxi propil metil celulose"
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
WO1996026718A3 (en) Controlled release tablet
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
SE9003904D0 (sv) Method for the manufacture of a pharmaceutical dosage form
ES2010466A6 (es) Formas de administracion solidas, de rapida desintegracion.
CA2140032A1 (en) Cross-linked amylose material for enzymatically controlled drug release
AU5816496A (en) Process for the depyrogenation of injectable pharmaceutical solutions
AU1858992A (en) 2-(1-piperidyl)ethanol derivatives, their preparation and their therapeutic application
NO973241D0 (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av hyperlipoproteinemi, hypertriglyceridemi, hyperlipidemi eller hyperkolesterolemi, eller arteriosklerose, eller for antikoagulativ b
NO973342D0 (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av cerebrale degenerative sykdommer
MY130959A (en) Oral preparation, comprising at least one pharmaceutical active compound in a matrix which is swellable in aqueous medium
AU1251295A (en) Substituted benzimidazole, processes for its preparation and its pharmaceutical use
AU4898790A (en) An erosion-controlled release system for active agents and a process for its preparation
FR2661180B1 (fr) (hydroxyproline 9) lhrh, son procede d'obtention et application comme medicament.

Legal Events

Date Code Title Description
MK1K Patent expired